Skip to content
value.today

RxFunction, Inc.

Total raised
$30 M
7 rounds on record
Latest round
$5 M
Oct 2022
First round on record
Dec 2017
Today
Private
No later event on record

Funding rounds

7 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of RxFunction, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2022$5 MNo. 7$2 to $10 million

RxFunction, Inc.: Raise no. 7, Oct 2022

Investors in this round

1 investor had bought by the notice of Nov 10, 2022: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $10 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$500,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Minnesota

People named in the notice

  • Lars E. Oddsson · Executive Officer, Director
  • Mary E. Anderson · Executive Officer, Director
  • Kevin E. Roche · Director
  • Richard E. Nigon · Director
  • Richard E. Offerdahl · Director
  • Robert E. Rinek · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cedar Point Capital, LLC (CRD 145116) · broker-dealer Cedar Point Capital, LLC (CRD 145116) · Edina, MinnesotaSold in AZ, CA, CT, FL, IL, IN, MA, MN, MT, NC, ND, NJ, NY, OR, PA, TX, WI

Remarks in the notice

  • On fees: “Represents the maximum commission payable if entire offering is sold.”

Signed by Mary E. Anderson, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 10, 2022. Read the notice at the SEC.

equitySEC
Jan 2021$4 MNo. 6$2 to $10 million

RxFunction, Inc.: Raise no. 6, Jan 2021

Investors in this round

33 investors had bought by the notice of Jan 24, 2022: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $5 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them, other: The underlying offering is complete and this amendment to the original Form D covers only the Common Stock issuable upon exercise of warrants sold in the underlying offering.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$82,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Minnesota

People named in the notice

  • Joseph Daniel Leach · Executive Officer
  • Lars E. Oddsson · Executive Officer, Director
  • Mary E. Anderson · Executive Officer, Director
  • Kevin Daniel Roche · Director
  • Richard Daniel Nigon · Director
  • Richard Daniel Offerdahl · Director
  • Robert Daniel Rinek · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cedar Point Capital, LLC (CRD 145116) · broker-dealer Cedar Point Capital, LLC (CRD 145116) · Edina, MinnesotaSold in AZ, CA, CT, FL, IL, IN, MA, MN, MT, NC, ND, NJ, NY, OR, PA, TX, WI

Remarks in the notice

  • On fees: “Reflects actual amount paid.”
  • On the amounts: “The underlying offering is complete. The Total Remaining to be Sold reflects $649,470 of Common Stock that is issuable upon exercise of outstanding warrants.”

Signed by Mary E. Anderson, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 24, 2022. Read the notice at the SEC.

optionsSEC
Nov 2020$4 MNo. 5$2 to $10 million

RxFunction, Inc.: Raise no. 5, Nov 2020

Investors in this round

2 investors had bought by the notice of Mar 18, 2021: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $6 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them, other: The underlying offering is complete and this amendment to the original Form D covers only the Common Stock issuable upon exercise of warrants sold in the underlying offering.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Minnesota

People named in the notice

  • Joseph Daniel Leach · Executive Officer
  • Lars E. Oddsson · Executive Officer, Director
  • Mary E. Anderson · Executive Officer, Director
  • Kevin H. Roche · Director
  • Richard H. Offerdahl · Director
  • Richard P. Nigon · Director
  • Robert P. Rinek · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The underlying offering is complete. The Total Remaining to be Sold reflects $2,000,000 of Common Stock that is issuable upon exercise of outstanding warrants.”

Signed by Mary E. Anderson, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Mar 18, 2021. Read the notice at the SEC.

optionsSEC
Mar 2020$4 MNo. 4$2 to $10 million

RxFunction, Inc.: Raise no. 4, Mar 2020

Investors in this round

41 investors had bought by the notice of Mar 16, 2021: 41 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them, other: The underlying offering is complete and this amendment to the original Form D covers only the Common Stock issuable upon exercise of warrants sold in the underlying offering.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$358,722
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Minnesota

People named in the notice

  • Joseph Daniel Leach · Executive Officer
  • Lars E. Oddsson · Executive Officer, Director
  • Mary E. Anderson · Executive Officer, Director
  • Kevin Daniel Roche · Director
  • Richard Daniel Nigon · Director
  • Richard Daniel Offerdahl · Director
  • Robert Daniel Rinek · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cedar Point Capital, LLC (CRD 145116) · broker-dealer Cedar Point Capital, LLC (CRD 145116) · Edina, MinnesotaSold in AZ, CA, CT, FL, IL, IN, MA, MN, MT, NC, ND, NJ, NY, OR, PA, TX, WI

Remarks in the notice

  • On fees: “This amount represents the actual amount paid. The underlying offering is complete.”
  • On the amounts: “The underlying offering is complete. The Total Remaining to be Sold reflects $275,978 of Common Stock that is issuable upon exercise of outstanding warrants.”

Signed by Mary E. Anderson, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 16, 2021. Read the notice at the SEC.

optionsSEC
Mar 2019$4 MNo. 3$2 to $10 million

RxFunction, Inc.: Raise no. 3, Mar 2019

Investors in this round

41 investors had bought by the notice of Oct 14, 2026: 41 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them, other: The underlying offering is complete and this amendment to the original Form D covers only the Common Stock issuable upon exercise of warrants sold in the underlying offerings.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$358,722
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Minnesota

People named in the notice

  • Lars Oddsson · Executive Officer, Director
  • Mary E. Anderson · Executive Officer, Director
  • Kevin Roche · Director
  • Richard Nigon · Director
  • Richard Offerdahl · Director
  • Robert Rinek · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cedar Point Capital, LLC (CRD 145116) · broker-dealer Cedar Point Capital, LLC (CRD 145116) · Edina, MinnesotaSold in AZ, CA, CT, FL, IL, IN, MA, MN, MT, NJ, NY, NC, ND, OR, PA, TX, WI

Remarks in the notice

  • On fees: “This amount represents the actual amount paid. The underlying offering is complete.”
  • On the amounts: “The underlying offering is complete. The Total Remaining to be Sold reflects $275,978 of Common Stock that is issuable upon exercise of outstanding warrants issued in the offering as reported on Form D filed on 4/3/2019.”

Signed by Mary E. Anderson, Chief Executive Officer. Source: SEC Form D and 6 amendments, newest notice filed Oct 14, 2026. Read the notice at the SEC.

optionsSEC
Mar 2018$2 MNo. 2$2 to $10 million

RxFunction, Inc.: Raise no. 2, Mar 2018

Investors in this round

2 investors had bought by the notice of Mar 29, 2018: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $4 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$350,000
Finders' fees
none
Paid to its own people
$695,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Minnesota

People named in the notice

  • Joseph D. Leach · Executive Officer, Director
  • Lars Oddsson · Executive Officer, Director
  • Mary E. Anderson · Executive Officer
  • Thomas E. Morizio · Executive Officer, Director
  • Kevin E. Roche · Director
  • Richard E. Nigon · Director
  • Robert E. Rinek · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cedar Point Capital, LLC (CRD 145116) · broker-dealer Cedar Point Capital, LLC (CRD 145116) · Edina, MinnesotaSold in AL, CA, CT, FL, IL, IN, MA, MN, MT, NC, ND, NJ, NY, OR, PA, TX, WA, WI

Remarks in the notice

  • On fees: “This amount represents the maximum amount of commissions payable to Cedar Point assuming all of the shares are sold.”
  • On the amounts: “Total amount sold does not include warrants to purchase up to 183,571 shares of Series A Preferred Stock at $0.56 per share issued in connection with the offering, which may never be exercised.”
  • On the use of proceeds: “Estimate of officer salaries to be paid in 2018.”

Signed by Mary E. Anderson, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 29, 2018. Read the notice at the SEC.

equity, optionsSEC
Dec 2017$8 MNo. 1$2 to $10 million

RxFunction, Inc.: Raise no. 1, Dec 2017

Investors in this round

48 investors had bought by the notice of Oct 14, 2026: 48 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them, other: The underlying offerings are complete and this amendment to the original Form Ds covers only the Common Stock issuable upon exercise of warrants sold in the underlying offerings.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$769,038
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Minnesota

People named in the notice

  • Lars Oddsson · Executive Officer, Director
  • Mary E. Anderson · Executive Officer, Director
  • Kevin Roche · Director
  • Richard Nigon · Director
  • Richard Offerdahl · Director
  • Robert Rinek · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cedar Point Capital, LLC (CRD 145116) · broker-dealer Cedar Point Capital, LLC (CRD 145116) · Edina, MinnesotaSold in AZ, CA, CT, FL, IL, IN, MA, MN, MT, NJ, NY, NC, ND, OR, PA, TX, WI

Remarks in the notice

  • On fees: “This amount represents the actual amount paid. The underlying offering is complete.”
  • On the amounts: “The underlying offerings are complete. The Total Remaining to be Sold reflects $587,500 of Common Stock issuable upon exercise of warrants issued in the offering as reported on Form D filed 12/28/2017.”

Signed by Mary E. Anderson, Chief Executive Officer. Source: SEC Form D and 4 amendments, newest notice filed Oct 14, 2026. Read the notice at the SEC.

optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • RxFunction, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2026).

    SEC Form D · Oct 2026

  • The industry group it chose in its notices: Manufacturing.

    SEC Form D · Nov 2022

That is all the official record says: RxFunction, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of RxFunction, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 48 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by RxFunction, Inc.
NameRoleNamed in
Lars E. OddssonExecutive officerOct 2025
Mary E. AndersonExecutive officerOct 2025
Joseph E. SchauerExecutive officerNov 2024
Joseph Daniel LeachExecutive officerMar 2022
Lars OddssonExecutive officerDec 2020
Mary AndersonExecutive officerSep 2020
Joseph D. LeachExecutive officerMar 2018
Thomas E. MorizioExecutive officerMar 2018
Kevin RocheDirectorOct 2026
Richard NigonDirectorOct 2026
Richard OfferdahlDirectorOct 2026
Robert RinekDirectorOct 2026
Kevin E. RocheDirectorOct 2025
Lars E. OddssonDirectorOct 2025
Mary E. AndersonDirectorOct 2025
Richard E. NigonDirectorOct 2025
Richard E. OfferdahlDirectorOct 2025
Robert E. RinekDirectorOct 2025
Kevin Daniel RocheDirectorMar 2022
Richard Daniel NigonDirectorMar 2022
Richard Daniel OfferdahlDirectorMar 2022
Robert Daniel RinekDirectorMar 2022
Kevin H. RocheDirectorMar 2021
Richard H. OfferdahlDirectorMar 2021
Richard P. NigonDirectorMar 2021
Robert P. RinekDirectorMar 2021
Joseph D. LeachDirectorDec 2020
Lars OddssonDirectorDec 2020
Joseph Daniel LeachDirectorSep 2020
Mary AndersonDirectorSep 2020
Richard J. NigonDirectorSep 2020
Thomas E. MorizioDirectorMar 2018